Published: 22 December 2017
Author(s): Andrea Rubboli
Section: Letter to the Editor

In the recent RE-DUAL PCI trial [1] where dual therapy of dabigatran, at the dose of both 110 and 150mg twice daily, and clopidogrel was compared with conventional triple therapy of warfarin, aspirin, and clopidogrel in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI), the occurrence of major adverse ischemic events, including death or thromboembolic events, or unplanned revascularization, was comparable with dual (110 and 150mg twice daily doses of dabigatran combined) and triple therapy (Fig.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.